CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

X4 Pharmaceuticals Inc's Quick Ratio

XFOR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2024, Quick Ratio deteriorated to 3.61 below X4 Pharmaceuticals Inc's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Quick Ratio than X4 Pharmaceuticals Inc in first quarter 2024. While Quick Ratio total ranking has improved so far during the I Quarter 2024 to 449, from total ranking in the third quarter 2023 at 493.

Explain Quick Ratio?
How much Cash & cash equivalents XFOR´s has?
What are XFOR´s Current Liabilities?


XFOR Quick Ratio (Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change 6.07 % -11.74 % 1.14 % 32.08 % 63.16 %
Y / Y Cash & cash equivalent Change -33.56 % 77.43 % 198.26 % 40.61 % 48.82 %
Quick Ratio MRQ 3.61 5.83 6.7 5.1 5.76
XFOR's Total Ranking # 449 # 493 # 364 # 654 #
Seq. Current Liabilities Change -7.85 % 15.23 % 15.27 % -13.34 % -23.31 %
Seq. Cash & cash equivalent Change -42.92 % 0.26 % 51.28 % -23.26 % 52.42 %



Quick Ratio first quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 194
Overall Market # 449


Quick Ratio Statistics
High Average Low
16.36 6.87 1.36
(Mar 31 2020)   (Mar 31 2019)




Financial Statements
X4 Pharmaceuticals Inc's Current Liabilities $ 22 Millions Visit XFOR's Balance sheet
X4 Pharmaceuticals Inc's Cash & cash equivalent $ 81 Millions Visit XFOR's Balance sheet
Source of XFOR's Sales Visit XFOR's Sales by Geography


Cumulative X4 Pharmaceuticals Inc's Quick Ratio

XFOR's Quick Ratio for the trailling 12 Months

XFOR Quick Ratio

(Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth 6.07 % -11.74 % 1.14 % 32.08 % 63.16 %
Y / Y Cash & cash equivalent TTM Growth -33.56 % 77.43 % 198.26 % 40.61 % 48.82 %
Quick Ratio TTM 5.31 5.87 4.95 3.9 3.78
Total Ranking TTM # 2157 # 408 # 2347 # 3489 #
Seq. Current Liabilities TTM Growth -7.85 % 15.23 % 15.27 % -13.34 % -23.31 %
Seq. Cash & cash equivalent TTM Growth -42.92 % 0.26 % 51.28 % -23.26 % 52.42 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the I Quarter 2024 to $22.41 millions, cumulative Quick Ratio decreased to 5.31 below the X4 Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 80 other companies have achieved higher Quick Ratio than X4 Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 408 to 2157.

Explain Quick Ratio?
How much Cash & cash equivalents XFOR´s has?
What are XFOR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 81
Healthcare Sector # 553
Within the Market # 2157


trailing twelve months Quick Ratio Statistics
High Average Low
11.55 6.21 3.46
(Jun 30 2020)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2024 MRQ Cash & cash equivalentMar 31 2024 MRQ Current Liabilities
Entera Bio Ltd   9.49 $ 9.189  Millions$ 0.968  Millions
Adverum Biotechnologies Inc   8.97 $ 193.328  Millions$ 21.549  Millions
Prime Medicine Inc   8.35 $ 204.105  Millions$ 24.441  Millions
Humacyte Inc   8.20 $ 115.505  Millions$ 14.087  Millions
Passage Bio Inc   8.14 $ 104.525  Millions$ 12.841  Millions
Scholar Rock Holding Corp  7.98 $ 238.432  Millions$ 29.887  Millions
Black Diamond Therapeutics Inc   6.84 $ 115.199  Millions$ 16.854  Millions
Springworks Therapeutics Inc   6.33 $ 436.583  Millions$ 68.917  Millions
Ginkgo Bioworks Holdings Inc   6.21 $ 840.440  Millions$ 135.431  Millions
Zura Bio Limited  6.12 $ 89.817  Millions$ 14.674  Millions
Cardiff Oncology inc   6.03 $ 67.187  Millions$ 11.147  Millions
Immunocore Holdings Plc  5.41 $ 832.821  Millions$ 154.050  Millions
Dyadic International Inc  5.32 $ 12.038  Millions$ 2.262  Millions
Fennec Pharmaceuticals Inc   5.20 $ 51.184  Millions$ 9.836  Millions
Iovance Biotherapeutics inc   4.94 $ 356.195  Millions$ 72.136  Millions
Editas Medicine Inc   4.45 $ 296.171  Millions$ 66.487  Millions
Twist Bioscience Corporation  4.35 $ 293.342  Millions$ 67.490  Millions
Curis Inc   4.09 $ 40.720  Millions$ 9.954  Millions
Biomx Inc   4.02 $ 43.007  Millions$ 10.707  Millions
Recursion Pharmaceuticals Inc   4.01 $ 296.326  Millions$ 73.920  Millions
Dbv Technologies S a   3.83 $ 101.525  Millions$ 26.483  Millions
Cognition Therapeutics inc   3.65 $ 34.671  Millions$ 9.503  Millions
Inhibrx Inc   3.62 $ 252.483  Millions$ 69.753  Millions
X4 Pharmaceuticals Inc  3.61 $ 80.869  Millions$ 22.408  Millions
Moderna Inc   3.58 $ 8,523.000  Millions$ 2,380.000  Millions
Immunitybio inc   3.17 $ 170.495  Millions$ 53.759  Millions
Vericel Corporation  3.03 $ 110.648  Millions$ 36.470  Millions
Intensity Therapeutics Inc   2.99 $ 7.458  Millions$ 2.493  Millions
Biocryst Pharmaceuticals Inc   2.82 $ 338.352  Millions$ 119.921  Millions
Exelixis Inc   2.58 $ 963.256  Millions$ 373.010  Millions

Date modified: 2024-05-08T15:34:55+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com